MOR

MorphoSys AG [MOR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MOR Stock Summary

Top MOR Correlated Resources

MOR


Top 10 Correlated ETFs

MOR


Top 10 Correlated Stocks

MOR


In the News

08:36 29 Mar 2024 MOR

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

04:15 29 Mar 2024 MOR

Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.

01:06 29 Mar 2024 MOR

MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?

Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.

01:00 29 Mar 2024 MOR

What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?

Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.

10:45 29 Mar 2024 MOR

Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline

Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer treatments.

08:51 29 Mar 2024 MOR

Novartis to buy cancer drug maker MorphoSys for €2.7 billion

Novartis AG has announced the acquisition of Germany-based cancer drug maker MorphoSys AG through a €2.7 billion deal. Unveiling the takeover on Monday, Novartis said the move would expand its oncology pipeline, relating to cancer treatments, alongside widening its footprint in haematology - blood disease studies.

11:05 29 Mar 2024 MOR

Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).

05:16 29 Mar 2024 MOR

Novartis acquiring cancer drug developer Morphosys for €2.7 billion

CNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.

04:55 29 Mar 2024 MOR

Novartis acquires cancer drug developer MorphoSys for $2.9 bln

Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)

02:39 29 Mar 2024 MOR

Why Is MorphoSys (MOR) Stock Up 50% Today?

Deal flow appears to be picking up, particularly in the world of big pharma and biotech stocks. MorphoSys (NASDAQ: MOR ) is the latest company to be reportedly in talks with Novartis (NYSE: NVS ) in a deal that would see its cancer drug portfolio rolled under Novartis' massive umbrella.

MOR Financial details

Company Rating
Strong Buy
Market Cap
2.74B
Income
-189.19M
Revenue
238.36M
Book val./share
1.3
Cash/share
18.16
Dividend
-
Dividend %
-
Employees
524
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
12.95
Forward P/E
-9.59
PEG
-2.21
P/S
5.02
P/B
37.61
P/C
1
P/FCF
-6.63
Quick Ratio
3.14
Current Ratio
3.57
Debt / Equity
12.97
LT Debt / Equity
12.68
-
-
EPS (TTM)
-0.46
EPS next Y
-1.89
EPS next Q
-0.08
EPS this Y
24.32%
EPS next Y
309.82%
EPS next 5Y
-313.58%
EPS last 5Y
11.24%
Revenue last 5Y
27.13%
Revenue Q/Q
-7.4%
EPS Q/Q
-245.45%
-
-
-
-
SMA20
-
SMA50
80%
SMA100
125%
Inst Own
2.44%
Inst Trans
0.26%
ROA
4%
ROE
96%
ROC
-0.11%
Gross Margin
77%
Oper. Margin
-81%
Profit Margin
35%
Payout
-
Shs Outstand
150.48M
Shs Float
150.04M
-
-
-
-
Target Price
-
52W Range
3.83-18.305
52W High
+0.72%
52W Low
+504.33%
RSI
70
Rel Volume
0.09
Avg Volume
2.16M
Volume
199.5K
Perf Week
0.55%
Perf Month
3.66%
Perf Quarter
194.8%
Perf Half Y
143.68%
-
-
-
-
Beta
0.613
-
-
Volatility
0.05%, 0.22%
Prev Close
-0.06%
Price
18.13
Change
-0.17%

MOR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.572.471.342.041.74
Net income per share
-0.810.74-3.85-1.11-1.38
Operating cash flow per share
-0.630.27-3.6-2.68-2.16
Free cash flow per share
-0.66-0.11-3.8-2.8-2.18
Cash per share
2.168.227.446.644.97
Book value per share
3.124.681.831.150.36
Tangible book value per share
2.774.15-6.95-7.94-8.29
Share holders equity per share
3.124.681.831.150.36
Interest debt per share
0.353.123.83.345.43
Market cap
4.01B3.08B1.11B458.44M1.23B
Enterprise value
4.01B3.28B1.31B395.55M1.71B
P/E ratio
-38.931.42-2.16-3.03-6.48
Price to sales ratio
55.859.396.191.655.16
POCF ratio
-50.0187.2-2.31-1.25-4.16
PFCF ratio
-47.82-218.64-2.19-1.2-4.12
P/B Ratio
10.154.954.542.9125.06
PTB ratio
10.154.954.542.9125.06
EV to sales
55.8210.027.321.427.16
Enterprise value over EBITDA
-40.5125.71-7.332.29-17.46
EV to operating cash flow
-49.9893.11-2.73-1.08-5.77
EV to free cash flow
-47.8-233.46-2.59-1.04-5.71
Earnings yield
-0.030.03-0.46-0.33-0.15
Free cash flow yield
-0.020-0.46-0.83-0.24
Debt to equity
0.110.511.332.1612.97
Debt to assets
0.090.190.130.140.31
Net debt to EBITDA
0.021.63-1.13-0.36-4.88
Current ratio
4.936.023.983.913.08
Interest coverage
-46.261.24-1.531.39-2.3
Income quality
0.780.360.942.431.56
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.510.160.440.30.36
Research and developement to revenue
1.510.431.251.071.19
Intangibles to total assets
0.090.040.460.520.59
Capex to operating cash flow
0.05-1.40.050.040.01
Capex to revenue
-0.05-0.15-0.15-0.05-0.01
Capex to depreciation
-0.59-5.92-2.59-1.45-0.27
Stock based compensation to revenue
0.090.030.010.010.11
Graham number
7.568.8212.65.353.33
ROIC
-0.210.53-0.39-2.58-0.36
Return on tangible assets
-0.230.06-0.37-0.13-0.23
Graham Net
1.470.94-9.3-9.05-8.97
Working capital
242.13M1.01B848.43M810.69M549.71M
Tangible asset value
349.9M550.33M-929.02M-1.09B-1.14B
Net current asset value
201.96M168.63M-1.18B-1.15B-1.16B
Invested capital
0.110.511.332.1612.97
Average receivables
19.19M55.09M87.81M99.07M77.5M
Average payables
8.94M29.11M60.67M56.18M33.48M
Average inventory
266.69K5.13M15.36M22.5M43.16M
Days sales outstanding
103.47100.06174.35147.3765.34
Days payables outstanding
321.81.89K836.41289.62177.56
Days of inventory on hand
8.7396.37235.27182.07388.22
Receivables turnover
3.533.652.092.485.59
Payables turnover
1.130.190.441.262.06
Inventory turnover
41.930.921.5520.94
ROE
-0.260.16-2.1-0.96-3.87
Capex per share
-0.03-0.37-0.2-0.11-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.60.460.390.471.57
Net income per share
2.41-0.32-0.54-0.881.28
Operating cash flow per share
-0.77-0.52-0.92-0.25-1.5
Free cash flow per share
-0.81-0.52-0.92-0.26-1.52
Cash per share
6.645.794.924.6918.16
Book value per share
1.150.710.23-0.491.3
Tangible book value per share
-7.95-8.21-8.7-3.1-30.25
Share holders equity per share
1.150.710.23-0.491.3
Interest debt per share
0.32.262.262.317.14
Market cap
458.22M496.29M939.36M869.62M336.78M
Enterprise value
395.32M485.62M1.04B964.3M814.21M
P/E ratio
0.35-2.83-3.17-1.821.74
Price to sales ratio
5.617.9617.6713.635.7
POCF ratio
-4.35-6.97-7.46-25.82-5.98
PFCF ratio
-4.13-6.93-7.45-24.61-5.9
P/B Ratio
2.915.1129.66-12.996.87
PTB ratio
2.915.1129.66-12.996.87
EV to sales
4.847.7919.4915.1113.78
Enterprise value over EBITDA
1.71-34.81-25.33-19.1330.24
EV to operating cash flow
-3.75-6.82-8.23-28.63-14.45
EV to free cash flow
-3.56-6.78-8.22-27.29-14.27
Earnings yield
0.72-0.09-0.08-0.140.14
Free cash flow yield
-0.24-0.14-0.13-0.04-0.17
Debt to equity
2.162.98.88-3.6912.97
Debt to assets
0.140.130.130.120.31
Net debt to EBITDA
-0.270.76-2.37-1.8817.73
Current ratio
3.913.63.573.143.08
Interest coverage
0.14-2.46-1.78-0.76-9.4
Income quality
-0.321.61.70.28-1.17
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.510.170.320.240.73
Research and developement to revenue
1.151.331.070.991.36
Intangibles to total assets
0.520.550.570.170.59
Capex to operating cash flow
0.050.0100.050.01
Capex to revenue
-0.07-0.010-0.03-0.01
Capex to depreciation
-2.2-0.15-0.03-0.61-0.34
Stock based compensation to revenue
0.040.030.20-0.03
Graham number
7.912.261.683.116.14
ROIC
-0.05-0.16-0.2-0.24-0.12
Return on tangible assets
0.29-0.04-0.08-0.070.06
Graham Net
-9.05-9.25-9.79-10.59-32.75
Working capital
810.69M685.68M621.17M543.76M549.71M
Tangible asset value
-1.09B-1.12B-1.19B-424M-1.14B
Net current asset value
-1.15B-1.18B-1.25B-1.37B-1.16B
Invested capital
2.162.98.88-3.6912.97
Average receivables
110.23M95.21M82.12M72.27M50.5M
Average payables
117.6M93.9M134.52M118.39M72.67M
Average inventory
26.69M29.76M53.5M71.13M66.3M
Days sales outstanding
123.82112.73145.982.3264.98
Days payables outstanding
225.17639.981.4K697.12175.54
Days of inventory on hand
141.55151.29838.24420.39383.79
Receivables turnover
0.730.80.621.091.39
Payables turnover
0.40.140.060.130.51
Inventory turnover
0.640.590.110.210.23
ROE
2.09-0.45-2.341.790.98
Capex per share
-0.0400-0.01-0.02

MOR Frequently Asked Questions

What is MorphoSys AG stock symbol ?

MorphoSys AG is a DE stock and trading under the symbol MOR

What is MorphoSys AG stock quote today ?

MorphoSys AG stock price is $18.13 today.

Is MorphoSys AG stock public?

Yes, MorphoSys AG is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap